Episode
Exploring the Intersection of Biotech and Corporate VC with Danjuma Quarless
- Podcast
- The NextGen VC Podcast
- Published
- Dec 10, 2024
- Duration seconds
- 2198
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/the-nextgen-vc-podcast-6617779/episodes/exploring-the-intersection-of-biotech-and-corporate-vc-with-danjuma-quarless/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-nextgen-vc-podcast-6617779/exploring-the-intersection-of-biotech-and-corporate-vc-with-danjuma-quarless.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this episode of the NextGen VC podcast, hosts Mike Hostetler and Jen sit down with Danjuma Quarless from AbbVie Ventures to delve into the world of corporate venture capital. Danjuma shares insights on how corporate VCs like AbbVie differ from traditional VCs, particularly in the biotech and pharmaceutical industries. Listeners will learn about the strategic focus of AbbVie Ventures, the importance of scientific and competitive differentiation in securing investment, and the fluid communication within AbbVie's ecosystem. Danjuma also shares his personal journey from a research scientist to a venture capitalist, offering valuable advice for those looking to break into the venture capital space. The podcast also touches on the current trends in biotech, the challenges and opportunities in various regional ecosystems, and the importance of promoting diversity within the venture capital industry. Tune in to hear about the latest innovations in biotech, the differences in investment approaches between various regions, and how AbbVie Ventures aims to build communities and support underrepresented groups in the industry.